@AndrewCaravello:
$NWBO ❓ If there was no real pathway to approval previously, why would Linda Powers submit to the MHRA? What was the 150-day assessment pathway all about?
Because regulatory readiness and legal authority are two separate systems and Linda Powers submitted strategically at the exact moment when both were converging.
✅ 1. The 150-Day Pathway Was Real and It Allowed Scientific Review to Begin
On December 20, 2023, Northwest Biotherapeutics submitted its Marketing Authorisation Application (MAA) for DCVax-L to the UK’s MHRA under the 150-day accelerated assessment pathway. This pathway is designed for innovative therapies targeting serious or life-threatening diseases, and it allows the MHRA to:
Validate and initiate review quickly
Complete a full scientific assessment in 150 “active” days (excluding any clock-stops)
Engage advisory committees like CHM to prepare for potential approval
That pathway existed and was fully operational.
✅ 2. However, There Was No Permanent Legal Pathway to License Autologous ATMPs from Specials Use
DCVax-L was unique:
Autologous and patient-specific
Produced one dose at a time using Flaskworks automation
Used under the UK’s “Specials” program since 2014
Tied to its production system and site by design
At the time of submission, the UK had no permanent statutory mechanism to license a product that was:
Made per patient
Delivered via automated, closed-loop systems
Previously available only under the Specials exemption
So while scientific review could proceed, legal authority to issue a marketing license still required a structural fix.
✅ 3. That Fix Was Already Under Construction and Linda Powers Knew It
This is the key point:
The MHRA had been actively preparing a next-generation regulatory framework to support exactly this kind of therapy.
Between 2021 and 2024, the MHRA publicly promoted:
Point-of-care manufacturing
Digital batch release
Closed-system automation
Control sites for decentralized oversight
This wasn’t vague ambition. It was regulatory engineering, designed for cell-based ATMPs made with platforms like Flaskworks.
So why did Linda Powers submit when she did?
Because she saw that the framework to support DCVax was already being built.
✅ 4. SI 2025 No. 87 Finalized the Framework, Right on Schedule
On June 17, 2025, the UK enacted Statutory Instrument 2025 No. 87, which:
Authorized decentralized, sterile, point-of-care production
Created Control Sites to oversee manufacturing from afar
Recognized closed, automated systems like Flaskworks as regulatory-compliant platforms
Empowered regulators to license the product, process, and facility as one unified therapeutic system
This law was not improvised. It was the final structural piece of a new ATMP regulatory system the MHRA had been designing for years.
And DCVax was the only commercial-stage therapy already operating inside that system.
✅ 5. The Submission Was Strategic, It Drove the Final Legal Alignment
Linda Powers didn’t file “too early.” She filed deliberately:
To initiate scientific review while the legal fix moved through Parliament
To ensure DCVax would be the first product ready when the new framework went live
To lock in the 150-day timeline, aligning with SI 2025 No. 87’s legal corridor for decision
The submission was not a mistake. It was a trigger, and the MHRA responded.
🧠 Final Answer
Linda Powers submitted DCVax-L to the MHRA at the exact moment when the scientific, technological, and legal systems were converging.
The 150-day assessment pathway was real. The regulatory architecture was forming. The legal fix was already planned.
She didn’t wait for permission. She submitted to a structure that was nearly complete, and helped finish building it.
That’s not premature. That’s predictive leadership.
➡️ Hence this post I created to explain exactly what was unfolding:
🔗 x.com/andrewcaravell…
Market Data 
Markets 
AI
